Better Therapeutics, Inc.: restructuring charge — Better Therapeutics cuts 35% of workforce to extend cash runway ahead of FDA decision for BT-001

Better Therapeutics, Inc.

Workforce reduction of approx 35% of employees, effective March 24, 2023.
Company estimates ~$400k in cash-based severance and benefits expenses in Q2 2023.
CEO Frank Karbe cites need to preserve cash for potential FDA marketing authorization and commercial launch of BT-001.
Actions taken due to industry volatility and to extend cash runway for critical milestones.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Better Therapeutics, Inc. announced a restructuring with charges of approximately $400 thousand (approximately 35% of its employees).

Type: restructuring
Charge: approximately $400 thousand
Headcount: approximately 35% of its employees

Exact text from the filing

On March 23 2023, Better Therapeutics, Inc. (the “Company”) announced a reduction in its workforce (the “Workforce Reduction”) of approximately 35% of its employees as part of a cost reduction initiative to improve its cash runway and focus on the long-term success of the company. The Company will complete this Workforce Reduction on March 24, 2023. The Company estimates that it will incur approximately $400 thousand in cash-based expenses related to severance and benefits in the second quarter of 2023.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-23-078255

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.